Improving drug synthesis using safer chemical reactions
Mild and Selective Cooperative-Base Mediated Hydrosilylations for Improved Drug Synthesis
This study is looking for better and safer ways to make medicines that can help treat different diseases, using a new method that could make the process easier and more effective for everyone.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Western Washington University NIH-funded |
| Lab location | 1 site (Bellingham, United States) |
| Project ID | NIH-10436072 on NIH RePORTER |
What this research studies
This research focuses on developing safer and more efficient methods for synthesizing drugs that can treat various human diseases. It aims to create a new approach using organosilanes and cooperative-base activation to perform reduction reactions, which are essential in drug development. By investigating selective reduction protocols, the research seeks to enhance the safety and effectiveness of drug synthesis, making it more accessible for clinical applications. The study will explore different reaction conditions to optimize the production of biologically active molecules.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals involved in drug development or those interested in the pharmaceutical industry, particularly in the context of new drug synthesis.
Not a fit: Patients who are not involved in drug development or who do not have a vested interest in pharmaceutical advancements may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more efficient drug synthesis methods, ultimately improving the availability of effective treatments for patients.
How similar studies have performed: While the approach is innovative, similar research has shown promise in improving drug synthesis methods, indicating potential for success.
Where this research is happening
Bellingham, United States
- Western Washington University — Bellingham, United States (Active)
Researchers
- Principal investigator: O'neil, Gregory W — Western Washington University
- Study coordinator: O'neil, Gregory W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.